Physician profile
Scott Hande
NPI 1083665962
$11,459.76
in general payments reported to CMS, 2019-2025
48 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $1,163 · 2021: $1,780 · 2022: $1,756 · 2023: $1,778 · 2024: $2,090 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,655 · Education: $63.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,655.25 |
| Education | $63.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,300.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,936.04 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,163.40 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $705.10 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $479.66 | 2019-2025 | |
| Pfizer INC. | $466.82 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $361.92 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $261.18 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $249.04 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $246.72 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $237.70 | 2022-2025 | Dupixent |
| Genzyme Corporation | $227.77 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $216.16 | 2019-2024 | |
| Ardelyx, INC. | $198.49 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $194.10 | 2019-2025 | Sucraid |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $159.21 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $152.15 | 2019-2025 | Ocaliva |
| Fresenius Kabi USA, LLC | $151.11 | 2023-2024 | |
| Celltrion USA INC. | $147.47 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Celgene Corporation | $139.73 | 2021-2024 | Zeposia |
| Organon LLC | $133.25 | 2023-2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $114.43 | 2020-2023 | Cimzia |
| Madrigal Pharmaceuticals | $114.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $107.31 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $99.71 | 2020-2022 | |
| Braintree Laboratories, INC. | $92.50 | 2020-2025 | Suflave |
| Daiichi Sankyo INC. | $84.34 | 2021-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.40 | 2023-2024 | Cyltezo |
| Shionogi INC | $67.60 | 2019 | |
| Allergan, INC. | $61.22 | 2019-2020 | |
| Shire North American Group INC | $57.39 | 2019 | |
| Romark Laboratories, Lc | $57.13 | 2020 | |
| Alfasigma USA, INC. | $47.59 | 2020-2021 | |
| Mylan Institutional INC. | $37.81 | 2023 | Hulio |
| Amgen INC. | $34.85 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Capsovision, INC. | $31.02 | 2023-2025 | Capsocam Plus |
| Ucb, INC. | $30.89 | 2019 | |
| Sandoz INC. | $23.96 | 2023 | Hyrimoz |
| Tersera Therapeutics LLC | $22.59 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.23 | 2022 | |
| Medtronic, INC. | $21.80 | 2022 | |
| Ethicon US, LLC | $21.72 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.61 | 2025 | Sutab |
| Agios Pharmaceuticals, INC. | $19.57 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $17.94 | 2021 | |
| Novo Nordisk INC | $17.23 | 2025 | Wegovy |
| Evoke Pharma, INC. | $16.85 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.